Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

729
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
729
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

756
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
756
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

650
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
650
Overview of Carbohydrate Metabolism01:19

Overview of Carbohydrate Metabolism

3.8K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
3.8K
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.3K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.3K
Drug Regulation01:25

Drug Regulation

3.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiorenal effects of therapies for type 2 diabetes and obesity.

The British journal of cardiology·2026
Same author

Metformin: Antidiabetic actions from cells to tissues.

Metabolism: clinical and experimental·2026
Same author

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Peptides·2026
Same author

Pharmacological therapies for type 2 diabetes: future approaches.

Diabetologia·2025
Same author

Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.

Peptides·2025
Same author

Diabetes and gout: another role for SGLT2 inhibitors?

Therapeutic advances in endocrinology and metabolism·2024
Same journal

Correction: Analysis of glycaemic control with a connected smart pen cap in adults with type 1 diabetes: a randomised, open-label, parallel-group trial.

Diabetologia·2026
Same journal

History of infertility, risk of type 2 diabetes and HbA<sub>1c</sub> levels in the Nurses' Health Study II.

Diabetologia·2026
Same journal

Delayed maturation of the milk microbiome in women with type 1 diabetes.

Diabetologia·2026
Same journal

Remodelling of body composition surrounding the diagnosis of type 2 diabetes in three longitudinal cohorts.

Diabetologia·2026
Same journal

SARS-CoV-2 and diabetes: a post-pandemic reappraisal.

Diabetologia·2026
Same journal

Degree of islet function preservation and continuous glucose monitoring in individuals undergoing total pancreatectomy with islet autotransplantation.

Diabetologia·2026
See all related articles

Related Experiment Video

Updated: Feb 25, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K

Metformin: historical overview.

Clifford J Bailey1

  • 1School of Life and Health Sciences, Aston University, Gosta Green, Birmingham, B4 7ET, UK. c.j.bailey@aston.ac.uk.

Diabetologia
|August 5, 2017
PubMed
Summary
This summary is machine-generated.

Metformin, a key type 2 diabetes medication, originated from Galega officinalis. Despite early setbacks, its safety and efficacy in managing blood glucose and insulin resistance led to its global adoption.

Keywords:
BiguanideDimethylbiguanideGalega officinalisGuanidineHistoryJean SterneMetforminReviewType 2 diabetes

More Related Videos

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Related Experiment Videos

Last Updated: Feb 25, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.2K
Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs
08:15

Understanding the Changes in Mitochondrial Morphology through Dynamic and Three-dimensional Fluorescence Micrographs

Published on: August 15, 2025

1.1K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.9K

Area of Science:

  • Pharmacology and Endocrinology: Focus on biguanide derivatives and their impact on glucose metabolism.

Background:

  • Metformin's origins trace back to Galega officinalis, a traditional remedy containing guanidine, identified for its blood glucose-lowering properties in 1918.
  • Early synthetic guanidine derivatives were used for diabetes but discontinued due to toxicity; metformin was later rediscovered and initially noted for influenza treatment.
  • Jean Sterne first reported metformin for diabetes in 1957, but it gained limited traction compared to more potent, ultimately withdrawn, biguanides.

Discussion:

  • Metformin's reputation was initially impacted by the toxicity of related biguanides (phenformin, buformin), leading to their discontinuation due to lactic acidosis risk.
  • Despite initial limitations, metformin's ability to address insulin resistance and hyperglycemia without significant weight gain or hypoglycemia risk gradually gained acceptance.
  • The UK Prospective Diabetes Study (UKPDS) in 1998 highlighted metformin's long-term cardiovascular benefits, solidifying its role as a first-line therapy for type 2 diabetes.

Key Insights:

  • Metformin effectively counters insulin resistance and hyperglycemia in type 2 diabetes without causing weight gain or hypoglycemia.
  • Long-term studies, such as the UKPDS, have demonstrated significant cardiovascular benefits associated with metformin use.
  • Metformin has evolved from a less-favored biguanide to the most prescribed oral glucose-lowering agent globally.

Outlook:

  • Metformin's established safety profile and therapeutic benefits continue to support its position as a cornerstone in type 2 diabetes management.
  • Ongoing research may uncover further therapeutic applications for metformin beyond its current glycemic control indications.
  • The enduring legacy of metformin underscores the importance of continued investigation into traditional medicines for novel pharmaceutical development.